Iodine-131 Rituximab Radioimmunotherapy: Durable Control of Follicular LymphomaPaul C Kruger1, David JL Joske2 and Harvey Turner J 3*
- *Corresponding Author:
- Harvey Turner J
Director, Department of Nuclear Medicine
Fremantle Hospital and Health Service
Fremantle, Western Australia
Tel: 61 08 9431 2888
Fax: 61 08 9431 2889
E-mail: [email protected]
Received date: July 30, 2014; Accepted date: September 23, 2014; Published date: September 26, 2014
Citation: Kruger PC, Joske DJL, Turner JH (2014) Iodine-131 Rituximab Radioimmunotherapy: Durable Control of Follicular Lymphoma. J Nucl Med Radiat Ther 5:191. doi: 10.4172/2155-9619.1000191
Copyright: © 2014 Kruger PC, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Aims: We evaluated the response and toxicity, after long-term follow up of Iodine-131 rituximab radioimmunotherapy in patients with follicular lymphoma under the routine clinical care of a single hematologist over a period of 12 years.
Materials and methods: Patients received 131I-rituximab radioimmunotherapy according to a standard, personalized dosimetry protocol predicated upon a prescribed whole body radiation absorbed dose of 0.75Gy. Four doses of maintenance rituximab were subsequently administered over 12 months.
Results: Response rate was 97% with 24(77%) patients experiencing a complete remission confirmed on 18F-fluorodeoxyglucose positron emission tomography-computerized tomography scan. The cohort of 3 patients with duodenal lymphoma all achieved complete remission lasting 4-5 years.
Disclosure statement: There is no conflict of interest to declare with the publication of this work. No author has a financial incentive associated with the publication of this article.
Conclusion: 131I-rituximab radioimmunotherapy is an effective, safe, affordable, repeatable treatment which does not compromise future therapy options upon relapse. It is practical, being administered on an outpatient basis, and referring physicians maintain governance of their patients.